Darzalex from J&J, Genmab scores FDA approval in frontline multiple myeloma use as Sanofi rival looms
As Sanofi awaits the FDA review of its multiple myeloma drug — J&J and Genmab’s established rival treatment Darzalex scored US approval for use in treatment-naïve patients.
Darzalex — known chemically as daratumumab — is a monoclonal antibody that locks on to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. On Thursday, the drug was approved on top of the standard-of-care combination of the chemotherapy bortezomib, thalidomide and the steroid dexamethasone (VTd) for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.